BDBM476425 1,2,3,4-tetrahydroisoquinolin-5-yl (3S)-4-[N2-(2-benzyl-2- azaspiro[4.5]dec-8-yl)-N6- (methylsulfonyl)-D-lysyl]-3- [(thiophen-2- ylmethyl)carbamoyl]piperazine-1- carboxylate::US10875851, Example 81
SMILES: CS(=O)(=O)NCCCC[C@@H](NC1CCC2(CCN(Cc3ccccc3)C2)CC1)C(=O)N1CCN(C[C@H]1C(=O)NCc1cccs1)C(=O)Oc1cccc2CNCCc12
InChI Key: InChIKey=XOPBEXNWCHLVKL-RSGXDSATSA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Coagulation factor XII (Homo sapiens (Human)) | BDBM476425![]() (1,2,3,4-tetrahydroisoquinolin-5-yl (3S)-4-[N2-(2-b...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.40 | n/a | n/a | n/a | n/a | n/a | n/a |
MERCK SHARP & DOHME CORP. US Patent | Assay Description The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIIa can be determined using a relevant purified serin... | US Patent US10875851 (2020) | |||||||||||
More data for this Ligand-Target Pair |